Classifying Alzheimer’s Disease Progression Using Histelide
This project aims to supplement Braak staging, the current gold standard for determining Alzheimer’s disease progression, using a quantitative antibody capture assay called histelide. Histelide allows us to quantify the amount of amyloid beta and phosphorylated tau proteins in post-mortem brain sections from patients across various stages of Alzheimer’s disease, while preserving the tissue for further immunohistochemistry and imaging. We will be analyzing the relationship between the concentration of these proteins and the stereological measurements of neurons from the same patients in order to better classify Alzheimer’s disease progression.
Message To SponsorThank you so much for supporting this program and for making this opportunity possible! I am immensely grateful for having the opportunity to continue my research full-time over the summer.
Major: Molecular & Cell Biology
Mentor: Lea Grinberg/ UC San Francisco
Sponsor: Chandra Research Fellows - Chandra Fund